Please ensure Javascript is enabled for purposes of website accessibility

Why Cronos Group Declined 17.7% in August

By Billy Duberstein – Sep 7, 2020 at 2:13PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An uninspiring earnings report sent shares backsliding in August.

What happened

Shares of Cronos Group (CRON 1.95%) declined 17.7% in August, according to data from S&P Global Market Intelligence. The Canadian cannabis stock declined after a downbeat earnings report early in the month that highlighted a number of problems going on in the legal weed industry in Canada.

A hand holds a paper bag with a picture of a marijuana leaf on it.

Image source: Getty Images.

So what

During the second quarter, Cronos reported revenue growth of 29%, but basically all of that growth came from the 2019 acquisition of Redwood Holding Group, a U.S.-based cannabidiol (CBD) company. Outside of that, Cronos' revenue barely grew on an organic basis.

Even more concerning was a negative gross margin of -30%, or -$3 million. That ugly looking number was mainly due to a $3.1 million inventory writedown. Pot stocks have a strange accounting rule they must follow regarding recording profits in inventory, and some previously recorded revenue had to be reversed due to plunging cannabis prices in Canada. Still, even without the inventory adjustment, gross profits would have only been $0.1 million, or 1%. Adjusted operating losses nearly doubled to -$31.3 million from-$16.8 million in the year-ago quarter.

Now what

As I would for all other cannabis stocks, I'd recommend steering clear of Cronos. The industry is in quite a difficult place right now, as oversupply has overwhelmed the stalling rollout of Canadian retail outlets, and high taxes are enabling difficult black market competition. Cronos is having to invest in R&D, sales and marketing, regulatory requirements, and production capacity all while having to contend with slow revenue growth and margin compression -- not a good combination.

One thing Cronos does have going for it is an excellent balance sheet, with just over $1.3 billion in cash and short-term investments, courtesy of a $1.8 billion investment from cigarette giant Altria (MO -0.62%) in March of 2019. However, if the industry doesn't work out its problems, Cronos' cash hoard will continue to dwindle over time. Even though Cronos' market cap is only $1.9 billion, it's still a speculative bet in a risky, quasi-legal industry.

Billy Duberstein has no position in any of the stocks mentioned. His clients may own shares of the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cronos Group Inc. Stock Quote
Cronos Group Inc.
$3.13 (1.95%) $0.06
Altria Group Stock Quote
Altria Group
$44.74 (-0.62%) $0.28

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.